Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 135

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 135
---
 the RP-3467 program is entered into prior to or following the Closing), and (b) 50% of the Net Proceeds, in the case of any other Disposition entered into following
the Closing.

“DTC” means The Depository Trust Company or any successor thereto.

“Efforts Disposition Period” means the period beginning on the Closing and ending on the [first (1)] anniversary of the Closing, in each case related to a Permitted Disposition or a Disposition.

“Equity Award CVR” means a CVR received by an Initial Holder in respect of his or her Options and/or RSUs, as
applicable.

“Existing Partnership” means each of the Company’s following collaborations:
(i) Debiopharm International S.A. (“Debiopharm”) to develop, manufacture and commercialize lunresertib pursuant to that certain Collaboration and License Agreement, by and between the Company and Debiopharm
International SA, dated July 14, 2025, as amended, restated, modified, replaced and novated from time to time (the “First Partnership Agreement”); (ii) Bristol-Myers Squibb Company to develop, manufacture and
commercialize on potential new product candidates for the treatment of cancer pursuant to that certain Collaboration and License Agreement, dated as of May 26, 2020, as amended, restated, modified, replaced and novated from time to time (the
“Second Partnership Agreement”); and (iii) DCx Biotherapeutics Corporation to out-license certain early-stage discovery platforms pursuant to that certain Asset Purchase and
License Agreement, dated as of May 1, 2025, as amended, restated, modified, replaced and novated from time to time (the “Third Partnership Agreement”).

“Existing Partnership Agreement” means each of the First Partnership Agreement, the Second Partnership
Agreement and the Third Partnership Agreement.

“Existing Partnership Percentage” means (i) for the period
beginning the date hereof and ending on the second (2) anniversary hereof, ninety percent (90%) of Net Proceeds, (ii) for the period beginning on the second (2) anniversary hereof and ending on the fourth (4) anniversary hereof, eighty five percent (85%) of Net Proceeds, (iii) for the period
beginning on the fourth (4) anniversary hereof and ending on the sixth (6) anniversary hereof, eighty percent (80%) of Net